GenSight Biologics announces presentation of 72-week data from the REVERSE & RESCUE Phase III trials of GS010 at the Annual Meeting of ARVO

Sonoma Eye 2019, Sonoma, CA

GenSight Biologics announces presentation of 72-week data from the REVERSE Phase III trial of GS010 at the 45th annual meeting of NANOS

9th EURETINA Winter Meeting, Prague, Czech Republic

ARVO Annual Meeting, Vancouver, BC, Canada

BioEurope Spring, Vienna, Austria

45th NANOS Annual Meeting, Las Vegas, Nevada, US

Oddo BHF Forum, Lyon, France

37th Annual J.P. Morgan Healthcare Conference, San Francisco (CA), USA

World Orphan Drug Congress Europe, Barcelona, Spain